Latest Materials News

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Horizon Oil Limited reported a 13% increase in production for FY25, driven by the Mereenie acquisition and infill drilling success, while completing a transformative acquisition of Thailand assets. Despite softer oil prices, the company declared a final unfranked dividend, underscoring robust cash flow and strategic growth.

RAS Technology Holdings Limited reported a robust 31% increase in revenue to A$21.3 million for FY25, alongside its first net profit after tax since listing, driven by strategic acquisitions and global expansion.

Austral Gold Limited reported a net loss of US$1.3 million for the first half of 2025, while completing refurbishment of its Casposo plant to diversify production. Despite operational challenges and increased costs, the company leans on shareholder support and strategic investments to manage liquidity pressures.

Medallion Metals has significantly expanded its sulphide Mineral Resource Estimate at the Ravensthorpe Gold Project to 950,000 ounces gold equivalent, underpinning a rapid move toward production with a feasibility study due in October and a Final Investment Decision expected by year-end.

Hartshead Resources has voluntarily suspended trading on the ASX pending a significant announcement about a well carry agreement linked to its P2607 Licence. The suspension is set to last until the announcement or early September.

EQ Resources has successfully commissioned a third XRT ore sorter at its Saloro tungsten operation, increasing sorting capacity by 50% and improving processing efficiency. An updated ore reserve estimate is expected in early Q4 2025, reflecting operational gains and stronger tungsten prices.

Greatland Resources Limited has reported a robust unaudited FY2025 result, generating $337.3 million net profit after tax from seven months of Telfer gold-copper mine operations, alongside a successful ASX listing and strong cash flow.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.

Lynas Rare Earths reports FY25 revenue growth amid profit decline, completes major capital projects, and launches a $750 million equity raise to fund its expansive Towards 2030 strategy.